Pur­due Pharma ends part­ner­ship to de­velop sleep disor­der drug

The News-Times - - BUSINESS - By Paul Schott

STAM­FORD — Pur­due Pharma an­nounced this week it would leave a part­ner­ship with Ja­panese phar­ma­ceu­ti­cal firm Ei­sai that focused on de­vel­op­ing a drug to treat sleep­wake dis­or­ders, in­clud­ing in­som­nia.

In move that comes nearly two months af­ter the U.S. Food and Drug Ad­min­is­tra­tion ac­cepted a new drug ap­pli­ca­tion for the Lem­borex­ant treat­ment, Ei­sai will make an un­spec­i­fied one-time pay­ment to buy out Pur­due’s rights to the pro­ject. Pur­due will no longer par­tic­i­pate or fund the de­vel­op­ment and com­mer­cial­iza­tion of Lem­borex­ant, and Ei­sai will take full re­spon­si­bil­ity for those ac­tiv­i­ties world­wide.

Stam­ford-based Pur­due and Ei­sai had shared the costs tied to Lem­borex­ant’s global clin­i­cal stud­ies and com­mer­cial­iza­tion, ac­cord­ing to their orig­i­nal

agree­ment, which was es­tab­lished in Au­gust 2015.

“As a re­sult of the on­go­ing diver­si­fi­ca­tion of our re­search prod­uct port­fo­lio, Pur­due’s busi­ness pri­or­i­ties have shifted since this col­lab­o­ra­tion was ini­ti­ated,” Pur­due CEO and Pres­i­dent Craig Lan­dau said in a state­ment. “This mu­tual de­ci­sion en­ables us to ded­i­cate our re­sources to our on­col­ogy, non-opi­oid pain, and other (cen­tral nervous system) pro­grams. Pur­due ap­pre­ci­ates the op­por­tu­nity to col­lab­o­rate with Ei­sai, and we wish them con­tin­ued success with the ad­vance­ment of Lem­borex­ant.”

Pur­due had pur­sued the de­vel­op­ment of Lem­borex­ant, as it grap­ples with more than 1,000 law­suits tied to the al­legedly fraud­u­lent mar­ket­ing of OxyCon­tin, its top-sell­ing drug. Last week, Con­necti­cut filed an ex­panded law­suit against the com­pany.

Mean­while, Pur­due is mov­ing for­ward with the de­vel­op­ment of a num­ber of other nono­pi­oid drugs.

A new Pur­due sub­sidiary gained FDA ap­proval in March for a drug called Ad­han­sia XR, to treat at­ten­tion deficit hy­per­ac­tiv­ity disor­der.

Also in March, Pur­due an­nounced an FDA fast-track des­ig­na­tion for a “nalme­fene hy­drochlo­ride” in­jec­tion to treat known or sus­pected opi­oid over­doses.

In the past three months, an­other new Pur­due sub­sidiary has se­cured the FDA’s “orphan drug des­ig­na­tion” for ex­pe­dited re­views of drugs to, re­spec­tively, treat rare bile-duct cancer and an ex­tremely rare type of leukemia. The com­pany said it will not profit from the lat­ter medication.

Last Jan­uary, Pur­due an­nounced it will part­ner with eye­care-phar­ma­ceu­ti­cal firm Oc­u­lar Ther­a­peu­tix on re­search aim­ing to de­velop non-opi­oid pain treatments.

In an­other non-opi­oid ini­tia­tive, Pur­due an­nounced last Oc­to­ber an “exclusive op­tion” to ac­quire Plymouth, Minn.-based Spine-Thera, which is de­vel­op­ing an in­jectable steroid treat­ment for back pain.

Drew Angerer / Getty Images

Pur­due Pharma is head­quar­tered at 201 Tresser Blvd. in down­town Stam­ford.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.